鼻咽癌血清中EB病毒核抗原-1和核抗原-2抗体的研究

INVESTIGATION ON ANTI-EBNA1 AND ANTI-EBNA2 ANTIBODIES IN NASO-PHARYNGEAL CARCINOMA (NPC)

用抗补体免疫荧光法检测鼻咽癌患者和对照人群中EB病毒核抗原-1(EBNA-1)和EB病毒核抗原-2(EBNA-2)抗体的水平。鼻咽癌组中两种抗体滴度都升高,以EBNA-1抗体上升明显;且EBNA-1抗体与总EBNA抗体水平的变化趋势相一致。鼻咽增生性病变组中EBNA-2抗体略占优势,该组中EBNA-2抗体水平升高可能与潜伏状态的EB病毒激活或再感染的早期阶段有关。

All of 195 sera from different stages of NPC patients contained antibody to EBNAl (GMT: 1:45.1). Antibody to EBNAl was significantly higher in NPC group than in the three groups: Nasopharyngeal Hyperplastic Lesion (NPHL), Other Tumor and Health Control. 192 sera out of 195 contained antibody to EBNA-2 (GMT: 1:20.4), which was higher in NPC group than in Health Control, but there was no significant difference in titers of anti-EBNA2 between NPC and NPHL groups. Since EBNAl and EBNA2 are associated with cell transformation and EBNA2 usually appears in the early stage of EBV latent infection and/or reinfection, a long-term follow-up study on antibodies to EBNAl and EBNA2 in the NPHL patients might provide prospective observation on the development of NPC.